Role of Adenosine in the Release of VEGF and Cytokines

• Status: Terminated
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to extend previous observations in animal models regarding the effects of adenosine in the release of cytokines to human subjects. We intend to accomplish this in two study protocols. In the first we will infuse intravenously adenosine and measure the plasma levels of inflammatory cytokines. In the second one, we will use a microdialysis technique to infuse intradermally small amounts of adenosine and will measure skin blood flow and will take a biopsy to measure levels of mRNA for cytokines.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Treatments: Adenosine; Nitroprusside

Criteria

Inclusion Criteria:

• Age 18-60 yr.

• All potential volunteers will have routine blood test to screen for hepatic, renal, and hematological abnormalities.

• Body mass index < 27 Kg/m2 .

• Female volunteers of childbearing potential will undergo HCG pregnancy test at screening and again on the study day.

Exclusion Criteria:

• Pregnancy females

• Subjects unable to give voluntary informed consent

• Subjects on anticoagulant drugs or anemic

• Subjects with a recent medical illness

• Subjects with a history of coronary heart disease

• Subjects with known kidney or liver disease

• Subjects with history of asthma

• Recent (past three days) use of phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil or vardenafil)

• History of intolerance to adenosine or nitroprusside

• History of methemoglobinemia

• Use of theophylline products

• Subjects with hematological abnormalities